SOLICITATION NOTICE
Q -- Survey the effects of cigarette smoking on oral microbiotas across 10 different Oral sites
- Notice Date
- 9/4/2013
- Notice Type
- Presolicitation
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- NCI-130157-TG
- Archive Date
- 10/3/2013
- Point of Contact
- Terry Galloway, Phone: 240-276-5384, Seena Ninan, Phone: 240-276-5419
- E-Mail Address
-
gallowaytl@mail.nih.gov, ninans@mail.nih.gov
(gallowaytl@mail.nih.gov, ninans@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E136, Bethesda, MD 20892, UNITED STATES Description National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Genetic Epidemiology Branch (GEB), plans to procure on a sole source basis services to survey the effects of cigarette smoking on oral microbiotas across 10 different oral sites from oral samples collected from 25 heavy smokers and 25 never smokers from the University of Maryland School of Medicine, Institute of Genome Sciences, 801 West Baltimore Street, Baltimore MD 21201. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1) and is exempt from the requirements of FAR Part 6. The North American Industry Classification System code is 541380 and the business size standard is $14.0 Million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The period of performance is twelve (12) months from date of award. It has been determined there are no opportunities to acquire green products or services for this procurement. Human microbial communities (microbiotas) play an important role in human health. The oral microbiotas are centrally related to nutrition, metabolism, immunity, inflammation, and endocrine balance. The oral cavity has the most diverse microbial communities among all the surveyed human body sites. In part, this is because microbiotas in the different sites of the same oral cavity vary widely. Recent studies indicated that the difference in microbial profiles between buccal mucosa and gingival plaque is as distinct as the difference between tongue and stool. Cigarette smoking is associated with serious health outcomes including cancer, cardiovascular disease and chronic lung disease. However, precisely how cigarette smoking leads to these health outcomes is still incompletely understood. One emerging hypothesis is that cigarette smoking might promote the colonization and overgrowth of certain human associated microbial species, which may lead to inflammation and adverse health outcomes including cancer. Cigarette smoking exposure increases the risk of several infectious diseases. Cigarette smoking has also been shown to promote the colonization of pathogens such as Porphyromonas gingivalis, Campylobacter retus, Prevotella intermedia, Tannerella forsythia, Treponema denticola and Fusobacterium nucleatum. Recently it was demonstrated that cigarette smoking could impair epithelial innate immune responses to microbial products, perhaps setting stage for microbial overgrowth and invasion. NCI will study information to determine whether cigarette smoking affects oral microbiotas and the degree of these effects on oral microbiotas across the 10 oral sites. The study will indicate promising oral sites for further studies of the relationship between cigarette-smoking and oral microbiotas. NCI DCEG GEB requires the contractor to provide the following from government provided samples (1) Total DNA from 500 oral samples; (2) Total RNA extraction from 450 oral samples (The mouthwash samples are not included.); (3) PCR amplification of the 16S rRNA gene using primers F319-R806 for 500 samples; (4) PCR products quantification and pooling; (5) lllumina sequencing library construction; (6) Sequencing of Illimuna MiSeq (250 bp paired-end reads); (7) Initial ioinformatics analysis - Quality analysis/control (remove low quality/short reads, reads containing homopolymeric repeat and chimeric reads); and (8) provide total DNA, RNA and denoised 16S rRNA gene sequence data. The University of Maryland Medical School, Institute of Genome Sciences (IGS), is uniquely qualified to provide this service. The University of Maryland IGS is a lead institution for the NIH Roadmap-sponsored Human Microbiome Project. A unique attribute of IGS is that it has previously collaborated with the NCI Infectious and Immunoepidemiology Branch (IIB), to characterize various methodological aspects of fecal microbiome stability, reproducibility, viability and enzymatic activity. A critical capability, is extraction of bacterial DNA and RNA that have been collected from human during routine evaluations, as well as the capability to PCR-amplify both generic and specific bacterial genes and transcripts. IGS can extract and amplify such bacterial DNA and RNA from human oral swabs, and it has demonstrated this to yield valid human microbiome data. No other source is known that can provide both techniques. IGS has access and experience with specialized tools required to deal with the enormous and highly specialized data sets that are generated. For example, a variety of unique informatics approaches are needed to assemble short-length sequence data (AMOS). IGS has experience with other highly specialized tools such as: IMG, the Integrated Microbial Genomes database and comparative analysis system; IMG/M, a related system that integrates metagenome data sets with isolate microbial genomes from the IMG system; and the Genomes OnLine Database (GOLD), for monitoring the status of genomic and metagenomic projects worldwide and their associated metadata. Using and coordinating these tools in the analysis of our data, as well as the comparison of new analyses with those previously conducted by IIB & GEB group, in the context of the Human Microbiome Project is a critical asset. This notice is not a request for competitive quotation. However, if any interested party especially small businesses, believes it can meet the above requirement, it may submit a capability statement, proposal, or quotation, which shall be considered by the agency. The responses and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Responses must be received in the contracting office by 11:00 AM EST, on September 18, 2013. All responses and questions must be in writing and faxed 240-276-5401 or emailed to Terry Galloway, Contracting Officer via electronic mail at gallowaytl@mail.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractors must be registered and have valid certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA) through sam.gov. Reference: NCI-130157-TG on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-130157-TG/listing.html)
- Record
- SN03174327-W 20130906/130905000412-6e2cadf35ab04f343eaa187f854631c6 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |